Welcome to our dedicated page for Translational Development Acquisition SEC filings (Ticker: TDACU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Translational Development Acquisition's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Translational Development Acquisition's regulatory disclosures and financial reporting.
Translational Development Acquisition Corp. is a SPAC that has not yet begun operating activities and is focused on completing its first business combination. As of June 30, 2026, assets totaled $157.4 million, largely in a trust account invested in money market funds, with cash outside the trust of $85,877 and a working capital deficit.
For the six months ended June 30, 2026, the company reported net income of $2.3 million, driven by $3.3 million of dividends on trust investments, partially offset by $0.9 million of general and administrative costs. During June 2026, holders redeemed 2,598,697 Class A shares for $27.8 million, reducing trust assets.
The SPAC entered into a Business Combination Agreement with ProLogium Holding Inc. and a related $50 million subscription for 5,000,000 Class A shares plus an equal number of warrants, both contingent on closing the transaction. The combination deadline was extended to June 24, 2027, but management discloses substantial doubt about the ability to continue as a going concern if no deal is completed by that date.
Meteora Capital, LLC and its managing member Vik Mittal report beneficial ownership of 919,000 shares of Translational Development Acquisition Corp. Class A Common Stock, representing 6.27 % of the class. All reported shares are held by funds and managed accounts for which Meteora Capital acts as investment manager, with no sole voting or dispositive power and shared voting and dispositive power over all 919,000 shares. The reporting persons state that the filing does not constitute an admission that they are beneficial owners of these shares for purposes of Section 13.
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC report beneficial ownership of 1,056,879 Class A ordinary shares of Translational Development Acquisition Corp. Both entities report 7.2% of the class.
They report 0 shares with sole voting or dispositive power and 1,056,879 shares with shared voting and shared dispositive power. Goldman Sachs & Co. LLC is identified as a broker-dealer and registered investment adviser, and as a subsidiary through which the parent holding company’s reportable ownership is held.
The reporting units of Goldman Sachs state that they disclaim beneficial ownership of securities held for certain client accounts or investment entities where interests are held by other persons.
Translational Development Acquisition Corp. entered into a Subscription Agreement with ProLogium Holding Inc. and Naetas Holding Limited, under which Naetas agreed to purchase 5,000,000 TDAC Class A ordinary shares at $10.00 per share, for an aggregate $50,000,000 private placement tied to TDAC’s pending business combination with ProLogium.
For no additional consideration, Naetas is also entitled to receive 5,000,000 Subscribed Warrants with terms substantially identical to TDAC’s public warrants, including a $11.50 exercise price, an $18.00 per-share redemption trigger and a $0.01 per-warrant redemption price, without ratchets or price resets beyond customary anti-dilution. The subscription is expected to close one business day before the first merger and is fully contingent on completion of the ProLogium business combination; funds will be held in escrow and returned, and any Subscribed Securities cancelled, if the deal does not close in the specified period.
The securities will be sold in an unregistered private placement relying on Section 4(a)(2) of the Securities Act to an institutional accredited investor. ProLogium agreed to use commercially reasonable efforts to register the resale of the resulting ProLogium shares and warrants, generally filing within 45 days after the business combination closing and targeting SEC effectiveness within defined timeframes.
Wolverine Asset Management, LLC, Wolverine Holdings, LLC, and managers Christopher L. Gust and Robert R. Bellick report beneficial ownership of 944,878 Translational Development Acquisition Corp. Class A Ordinary Shares. Each reporting person has shared voting and dispositive power over these shares, with no sole voting or dispositive authority.
The disclosure states this represents 4.89% of the outstanding Class A Ordinary Shares. The percentage is based on 19,308,802 shares outstanding, derived from 21,907,499 shares outstanding as of June 12, 2026, minus 2,598,697 shares redeemed at the June 17, 2026 shareholders' meeting. The reporting persons indicate they own 5 percent or less of this class.
Translational Development Acquisition Corp. (TDAC) filed a current report to highlight progress on its planned merger with ProLogium Holding Inc.. The company announced that ProLogium has submitted an initial Registration Statement on Form F-4 to the SEC, an important step in the de‑SPAC process for the business combination first announced on May 27, 2026. TDAC’s CEO Michael Hoffman said the filing should give investors a fuller view of ProLogium’s history and details of the proposed transaction, though the registration statement remains subject to SEC review and potential revision. The forward‑looking statement section emphasizes numerous risks, including meeting a $250 million Minimum Cash condition, obtaining shareholder approvals, managing redemptions and financing needs, commercializing ProLogium’s solid‑state battery technology, and competing effectively after the combination.
Translational Development Acquisition Corp. reported the results of shareholder redemptions tied to a vote extending the SPAC’s deadline to complete its initial business combination with ProLogium Holding Inc. Public shareholders redeemed 2,598,697 Class A shares, while holders of 14,651,303 redeemable Class A shares chose to remain invested. After these redemptions, approximately $156.8mm remains in the trust account, which will help support the proposed business combination if it closes. Management highlighted that about 85% of shareholders did not redeem, viewing this as support for the planned merger with ProLogium, a developer of next‑generation lithium ceramic battery technology.
Translational Development Acquisition Corp. obtained shareholder approval to extend the deadline to complete a business combination by up to twelve one-month periods from June 24, 2026 to June 24, 2027. This required amendments to both its charter and its investment management trust agreement.
Each one-month extension will require a deposit into the trust account of the lesser of $200,000 and $0.03 per outstanding public share, paid two days before the extension after five days’ advance notice to the trustee. At the meeting, about 79.56% of outstanding shares were represented, and all three proposals, including the extension and trust amendments, passed with 16,621,609 votes for and 809,296 against. In connection with the extension approval, holders of 2,598,697 Class A shares elected redemption at approximately $10.70 per share, totaling about $27,817,433.95, leaving 14,651,303 Class A IPO shares outstanding.
Translational Development Acquisition Corp. reported that on June 12, 2026 it converted 4,657,499 Class B ordinary shares held by its sponsor into an equal number of Class A ordinary shares. These new Class A shares carry the same restrictions that applied to the Class B shares, including transfer limits, waived redemption rights and an obligation to vote in favor of an initial business combination.
After the conversion, 21,907,499 Class A ordinary shares and one Class B ordinary share were issued and outstanding. The transaction generated no cash for the company, did not change the amount in the trust account and did not alter the per-share redemption value of the public Class A shares, which was approximately $10.69 per public share as of June 12, 2026.
Translational Development Acquisition Corp. Schedule 13G discloses that Linden Advisors and Siu Min (Joe) Wong may be deemed beneficial owners of 950,000 shares of Class A Ordinary Shares as of May 27, 2026, representing approximately 5.5% of the outstanding shares. The filing states that 913,482 shares are held by Linden Capital and 36,518 shares are held by one or more Managed Accounts; Linden GP and Linden Capital are each deemed beneficial owners of the 913,482 shares (about 5.3%).
The statement lists voting and dispositive powers as shared (no sole voting or sole dispositive power reported) and provides addresses and organizational details for Linden Capital, Linden GP, Linden Advisors, and Mr. Wong.